BOUNDLESS BIO, INC. Deferred Tax Assets, Operating Loss Carryforwards
BOUNDLESS BIO, INC. (BOLD) had Deferred Tax Assets, Operating Loss Carryforwards of $45.57 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $45.57M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $27.62M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $18.33M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $45.57M 10-K · filed 2026-03-09 |
| 2024-12-31 | $27.62M 10-K · filed 2026-03-09 |
| 2023-12-31 | $18.33M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |